David Altshuler

David Altshuler is an American physician-scientist and geneticist renowned for his foundational contributions to the field of human genomics. He played a leading role in major international consortia, including the International HapMap Project and the 1000 Genomes Project, which mapped human genetic variation. His research has significantly advanced the understanding of the genetic architecture of common diseases, particularly type 2 diabetes, and has bridged the gap between genomic discovery and drug discovery. Altshuler has held prominent positions in both academia and the biotechnology industry, serving as a professor at Harvard Medical School, a founding core member of the Broad Institute, and later as Chief Scientific Officer at Vertex Pharmaceuticals.

Early life and education

David Altshuler was born in New York City and developed an early interest in science. He pursued his undergraduate studies at the Massachusetts Institute of Technology, where he earned a Bachelor of Science degree. He then entered the prestigious Medical Scientist Training Program at Harvard University, completing both an M.D. and a Ph.D. in genetics. His doctoral work, conducted under the mentorship of renowned geneticists, laid the groundwork for his future research in population genetics and complex trait analysis. This training at premier institutions like MIT and Harvard provided a strong foundation in both clinical medicine and basic research.

Career and research

Altshuler began his independent career as a faculty member at Harvard Medical School and Massachusetts General Hospital. He quickly became a central figure at the newly formed Broad Institute, serving as a founding core member and director of its Program in Medical and Population Genetics. His leadership was instrumental in large-scale collaborative science, co-chairing the International HapMap Consortium and contributing to the 1000 Genomes Project. In a significant career shift, he moved to the biotechnology industry in 2014, joining Vertex Pharmaceuticals as Deputy Director and later Chief Scientific Officer, where he applied genomic insights to therapeutic development. He has also served on the board of directors for Denali Therapeutics and contributed to advisory councils for the National Institutes of Health.

Scientific contributions

Altshuler's scientific work has been pivotal in cataloging human genetic variation and applying it to disease research. He was a key architect of the HapMap Project, which created a public resource of SNPs and haplotype patterns across global populations, enabling the genome-wide association study (GWAS) era. His group conducted landmark GWAS for type 2 diabetes, identifying novel risk loci in genes like TCF7L2. He also made contributions to understanding the genetics of lipid levels, inflammatory bowel disease, and pharmacogenomics. His research helped transition the field from linkage studies to association mapping and emphasized the importance of allele frequency and population stratification in study design.

Awards and honors

In recognition of his work, Altshuler has been elected a fellow of several distinguished societies. He is a fellow of the American Association for the Advancement of Science and a member of the American Society for Clinical Investigation. He received the Dickson Prize in Medicine from the University of Pittsburgh. His contributions to genomics have been acknowledged through invited lectureships and prizes, including awards from the American Diabetes Association. His election to the National Academy of Medicine stands as a testament to his impact on medical science.

Personal life

David Altshuler maintains a private personal life. He is married and has children. Colleagues describe him as a collaborative and visionary scientist who effectively bridged the academic and industrial sectors of biomedical research. His career trajectory from leading academic consortia to guiding research strategy at a major biopharmaceutical company like Vertex reflects a deep commitment to translating genetic discoveries into tangible patient benefits.

Category:American geneticists Category:1965 births Category:Living people Category:Harvard Medical School faculty Category:Broad Institute people